Stock Taper
SCREENER COMPARE ANY 2 STOCKS
VTVT
VTV THERAPEUTICS INC.
NASDAQ
$32.36
▼ DOWN 1.34% (-0.44)

KEY STATISTICS

Market Cap$84.69 M
52w High$44.00
52w Low$17.00
Dividend Yield—
Frequency—
P/E-30.53
Volume90.24K
Shares Out.2.62M

COMPANY

LEADERSHIP

Paul J. Sekhri
CHIEF EXECUTIVE
Paul J. Sekhri

COMPENSATION 2026

Salary$673,000
Stock Awards$0
Incentive Plan Pay$343,230
All Other Comp.$20,310
Total$6,638,252

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 30, 2015
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
26

PRICE TARGET

Target High$42.00
Target Low$42.00
Target Median$42.00
Target Consensus$42.00

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$333.33K
NOV
5
THU

SPLIT RECORD

DATETYPERATIO
2023-11-21Reverse1:40

PRICE

$32.36 ▼ DOWN 1.34% (−$0.44)
OVERLAYS
$32.00$32.50$33.00$33.509:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM32.36

About vTv Therapeutics Inc.

https://www.vtvtherapeutics.com ↗

vTv Therapeutics Inc., a clinical-stage biopharma firm, develops oral treatments for diabetes, inflammatory diseases, and chronic conditions, with programs targeting glucokinase activation, PDE4 inhibition, Nrf2 pathways, and collaborations worldw...

INDUSTRY

Biotechnology

A PRODUCT VTV THERAPEUTICS INC. IS KNOWN FOR

Cadisegliatin (TTP399)
Cadisegliatin (TTP399)

Cadisegliatin is a liver-selective glucokinase activator in Phase 3 trials, developed as a potential adjunct to insulin for type 1 diabetes, with FDA Breakthrough Therapy designation and topline data expected in late 2026.

COMPETITORS

COMPETITOR
LLY COMPARE
NVO COMPARE
SABS COMPARE
VRTX COMPARE

Revenue by Products

IconPRODUCTQ1-2026Q2-2026
Reportable Segment$36.8M $36.8M

ETFS HOLDING THIS STOCK

ETFS HOLDING
14
LISTED HERE
4
RANKED BY POSITION SIZE
VTS.AX
0.00% · 60.8K
IWC
0.02% · 7.3K
QQQS
0.48% · 3.4K
AVSC
0.00% · 576

INSTITUTIONAL OWNERSHIP

SHARES OWNED
88.96%
HOLDERS
66
TOP 12 OF 66 · RANKED BY POSITION SIZE
Samsara Biocapital, LLC
374.5K sh · $8.74M
Millennium Management LLC
269.9K sh · $10.16M
Fmr LLC
268.9K sh · $10.75M
Blackrock Fund Advisors
245.2K sh · $1.18M
Veritable, L.P.
242.9K sh · $179.72K
Pathstone Family Office, LLC
242.9K sh · $116.12K
Wall Street Associates
164.9K sh · $797K
Siren, L.L.C.
163.0K sh · $6.46M
Baker Bros. Advisors LP
148.3K sh · $5.58M
Vanguard Group Inc
83.4K sh · $3.34M
Blackrock Institutional Trust Company, N.A.
74.3K sh · $359K
Aisling Capital Management LP
50.0K sh · $1.88M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
DIRECTOR
AKKARAJU SRINIVAS
Purchase · 6.0K shares
2026-06-26
★
DIRECTOR
BAKER BROS. ADVISORS LP
Purchase · 6.0K shares
2026-06-26
★
DIRECTOR
Al-Marzooqi Fahed
Purchase · 6.0K shares
2026-06-26
★
DIRECTOR
Phillips Anne M.
Purchase · 6.0K shares
2026-06-26

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
2 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY BTIG BUY

SECTORS PEERS

PEERPRICE
SPRB$60.78COMPARE
OTLK$0.64COMPARE
FBIO$2.77COMPARE
GANX$1.77COMPARE
OSTX$1.64COMPARE
NRXP$3.55COMPARE
INKT$11.43COMPARE
HOWL$0.94COMPARE